Literature DB >> 25913764

Neuropsychological differentiation between Alzheimer's disease and dementia with Lewy bodies in a memory clinic.

Yoshinari Kawai1, Rina Miura, Masashi Tsujimoto, Takashi Sakurai, Akiko Yamaoka, Akinori Takeda, Yutaka Arahata, Yukihiko Washimi, Teruhiko Kachi, Kenji Toba.   

Abstract

OBJECTIVE: The aim of this study was to identify a useful neuropsychological instrument for making a differential clinical diagnosis between Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).
METHODS: We examined 402 AD and 38 DLB patients with neuropsychological tests that covered general cognition, frontal lobe cognitive function, non-verbal abstract reasoning, working memory and attention, and verbal memory. Discriminant analysis using a stepwise method was performed to identify the measures best able to discriminate between AD and DLB.
RESULTS: The AD patients performed significantly worse than the DLB patients on orientation to time, delayed recall subtests on the Mini-Mental State Examination, and logical memory subtests 1 and 2 of the Revised Wechsler Memory Scale. The DLB patients performed significantly worse than the AD patients on the attention, repetition, and pentagon copying subtests of the Mini-Mental State Examination, the constructional praxis subtests of the Alzheimer's Disease Assessment Scale-cognitive component-Japanese version, the Frontal Assessment Battery total score, Raven's Coloured Progressive Matrices (RCPM) sets A, AB, and B, and backward digit span. Discriminant analyses between AD and DLB established the key variables as Logical Memory 1, Logical Memory 2, backward digit span, RCPM, and delayed recall on the Mini-Mental State Examination. We inferred the AD-DLB discriminant index from the following discriminant analyses: AD-DLB discriminant index = (Backward digit span score + RCPM set B score) - (Logical Memory 1 score + Logical Memory 2 score), which offered a highly favourable value for diagnostic utility.
CONCLUSIONS: The AD-DLB discriminant index, consisting of backward digit span, RCPM set B, and logical memory 1 and 2, is useful to differentiate between AD and DLB.
© 2013 The Authors. Psychogeriatrics © 2013 Japanese Psychogeriatric Society.

Entities:  

Keywords:  Alzheimer's disease; Lewy body disease; neuropsychological tests

Mesh:

Year:  2013        PMID: 25913764     DOI: 10.1111/psyg.12019

Source DB:  PubMed          Journal:  Psychogeriatrics        ISSN: 1346-3500            Impact factor:   2.440


  5 in total

1.  A Mini-Mental State Examination Formula May Help to Distinguish Alzheimer's Disease from Dementia with Lewy Bodies.

Authors:  Tom Ala; Danah Bakir; Srishti Goel; Nida Feller; Albert Botchway; Cindy Womack
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

2.  Frontal Assessment Battery in Early Cognitive Impairment: Psychometric Property and Factor Structure.

Authors:  W Y Goh; D Chan; N B Ali; A P Chew; A Chuo; M Chan; W S Lim
Journal:  J Nutr Health Aging       Date:  2019       Impact factor: 4.075

3.  Improvement of Visuo-spatial Function Assessed by Raven's Colored Progressive Matrices in Dementia with Lewy Bodies by Donepezil Treatment.

Authors:  Yuta Yoshino; Takaaki Mori; Taku Yoshida; Yasutaka Toyota; Hideaki Shimizu; Jun-Ichi Iga; Shusaku Nishitani; Shu-Ichi Ueno
Journal:  Clin Psychopharmacol Neurosci       Date:  2017-08-31       Impact factor: 2.582

4.  Risk prediction models for dementia constructed by supervised principal component analysis using miRNA expression data.

Authors:  Daichi Shigemizu; Shintaro Akiyama; Yuya Asanomi; Keith A Boroevich; Alok Sharma; Tatsuhiko Tsunoda; Kana Matsukuma; Makiko Ichikawa; Hiroko Sudo; Satoko Takizawa; Takashi Sakurai; Kouichi Ozaki; Takahiro Ochiya; Shumpei Niida
Journal:  Commun Biol       Date:  2019-02-25

5.  Prognosis prediction model for conversion from mild cognitive impairment to Alzheimer's disease created by integrative analysis of multi-omics data.

Authors:  Daichi Shigemizu; Shintaro Akiyama; Sayuri Higaki; Taiki Sugimoto; Takashi Sakurai; Keith A Boroevich; Alok Sharma; Tatsuhiko Tsunoda; Takahiro Ochiya; Shumpei Niida; Kouichi Ozaki
Journal:  Alzheimers Res Ther       Date:  2020-11-10       Impact factor: 6.982

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.